Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Gennyne Walker"'
Autor:
Gennyne Walker, Ryan Adams, Lauren Guy, Abhijeeth Chandrasekaran, Nelson Kinnersley, Pavithra Ramesh, Lu Zhang, Fran Brown, Vis Niranjan
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Preliminary evidence for efficacy in pulmonary sarcoidosis has been shown for efzofitimod. Here we present supportive evidence of efficacy based on an exposure-response analysis.Methods: Data from two studies (Phase 1, N = 24, single dose
Externí odkaz:
https://doaj.org/article/3f7393ecf74b4edbbe2b6fa84a82a5d3
Autor:
Daniel A. Culver, Shambhu Aryal, Joseph Barney, Connie C.W. Hsia, W. Ennis James, Lisa A. Maier, Lucian T. Marts, Ogugua Ndili Obi, Peter H.S. Sporn, Nadera J. Sweiss, Sanjay Shukla, Nelson Kinnersley, Gennyne Walker, Robert Baughman
Publikováno v:
Chest.
Pulmonary sarcoidosis is characterized by the accumulation of immune cells that form granulomas affecting the lungs. Efzofitimod (ATYR1923), a novel immunomodulator, selectively binds neuropilin-2, which is upregulated on immune cells in response to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3480c3db2c168e19de631450c3670aa8
https://pubmed.ncbi.nlm.nih.gov/36356657
https://pubmed.ncbi.nlm.nih.gov/36356657
Autor:
Erwan Gasnier, David Vissiere, Laurent Servais, Tahseen Mozaffar, Gennyne Walker, Kathryn R. Wagner, John Vissing, Teresa Gidaro, M. Annoussamy, Sanjay S. Shukla, Stanley Iyadurai, Shahram Attarian
Publikováno v:
MusclenerveREFERENCES. 65(2)
INTRODUCTION/AIMS Limb girdle muscular dystrophy type 2B (LGMDR2) and facioscapulohumeral muscular dystrophy (FSHD) are genetic muscular dystrophies with an increasing number of potential therapeutic approaches. The aim of this study is to report the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c297deefa536deb7b918d726a638be89
https://pubmed.ncbi.nlm.nih.gov/34687225
https://pubmed.ncbi.nlm.nih.gov/34687225
Autor:
Lauren Sitts, Leslie A. Nangle, Lisa Carey, Ryan Andrew Adams, Nelson Kinnersley, Lauren Guy, Gennyne Walker, Sanjay S. Shukla
Publikováno v:
Clinical problems.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f35f61e21f93fc9707f8adc37a2cfe9
https://doi.org/10.1183/13993003.congress-2021.pa452
https://doi.org/10.1183/13993003.congress-2021.pa452
Autor:
Kurt R. Stenmark, Albert F. Defelice, Stephen L. Archer, Ralph T. Schermuly, Gennyne Walker, Duncan J. Stewart, Steven Evans, Thomas R. Martin, Muriel Saulnier, Hubert Truebel, Monica L. Fiszman, Marlene Rabinovitch, Nicholas W. Morrell
Publikováno v:
Pulmonary Circulation
Pulmonary arterial hypertension (PAH) remains a life-limiting condition with a major impact on the ability to lead a normal life. Although existing therapies may improve the outlook in some patients there remains a major unmet need to develop more ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e00987ac4a8fced79fdc49223c3d3766
http://europepmc.org/articles/PMC3641734
http://europepmc.org/articles/PMC3641734
Autor:
Gennyne Walker, Brooke C. Harrison, Linda S. Henderson, Christopher Dufton, Arun Mandagere, Mindy Magee, Ramesh Boinpally
Publikováno v:
Clinical Drug Investigation. 30:875-885
Background: Ambrisentan is a once-daily, endothelin (ET) type A receptor-selective antagonist approved for the treatment of pulmonary arterial hypertension. Ambrisentan is primarily metabolized by glucuronidation and undergoes cytochrome P450 (CYP)-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bc1fc9d3d85cc8271cea5c07a303bd1
https://doi.org/10.2165/11539110-000000000-00000
https://doi.org/10.2165/11539110-000000000-00000
Publikováno v:
The Journal of Clinical Pharmacology. 49:719-724
Ambrisentan is an endothelin type A (ET(A))-selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative metabolism by CYP3A4. The potential for ketoconazole, the archetypal strong inhibitor of CYP3A4, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51fd565f3bcf58acefe10be79a51d29c
https://doi.org/10.1177/0091270009335870
https://doi.org/10.1177/0091270009335870
Autor:
Jorge A, Gutierrez, Ewa, Karwatowska-Prokopczuk, Sabina A, Murphy, Luiz, Belardinelli, Ramin, Farzaneh-Far, Gennyne, Walker, David A, Morrow, Benjamin M, Scirica
Publikováno v:
Clinical cardiology. 38(8)
BACKGROUND: Ranolazine, a piperazine derivative with anti‐ischemic effects, reduces the frequency of angina and improves exercise performance in patients with chronic angina. The effects of ranolazine in patients with established ischemic heart dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9aa6de90e628678a267197fe6da6c9b0
https://pubmed.ncbi.nlm.nih.gov/26059896
https://pubmed.ncbi.nlm.nih.gov/26059896
Autor:
Bernard deBruyne, Ehtisham Mahmud, Ann Olmsted, Gilles Montalescot, Gennyne Walker, Ramin Farzaneh-Far, Ori Ben-Yehuda, E. Magnus Ohman, Karen P. Alexander, Giora Weisz, Harvey D. White, Amir Lerman, Gregg W. Stone
Publikováno v:
American heart journal. 166(6)
Background Incomplete revascularization (ICR) after percutaneous coronary intervention (PCI) is common and is associated with increased rates of rehospitalization, revascularization, and mortality. Adjunctive pharmacotherapy with ranolazine, an inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5caa0405e291af62396bfa1dac244b1
https://pubmed.ncbi.nlm.nih.gov/24268208
https://pubmed.ncbi.nlm.nih.gov/24268208
Publikováno v:
B58. TREATMENT OF PULMONARY ARTERIAL HYPERTENSION.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c4a7610e051667a2f7a6c84085f9d21
https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3331
https://doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3331